 This study found that patients with inflammatory bowel disease, IBD, who also have ankylosing spondylitis, AS, are more likely to be prescribed biologic or small molecule treatments compared to those with IBD alone. Additionally, patients with ulcerative colitis and AS are at a greater risk of receiving these treatments than those with ulcerative colitis alone. These findings suggest that patients with IBD and AS should receive special attention when it comes to their treatment options. This article was offered by Yu Kyung-Joon, Hyuk-Yoon, Song Joon-Ko, and others.